PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide.

Inclusion Criteria

• •1. Male age ≥ 18 years
• •2. Histologically confirmed adenocarcinoma of the prostate
• •3. ECOG Performance Status ≤ 2
• •4. Castration resistance must be documented with surgical or medical castration with serum testosterone \< 50 ng/mL (\< 2.0 nM).
• •5. Men diagnosed with at least one metastatic lesion on CT or bone scan.
• •6. Documented biochemical and/or radiographic progression to previous treatment according to PCWG2 criteria.
• •7. Patients who are candidates for standard of care treatment with enzalutamide 160 mg every 24 hours.
• •8. Availability of formalin-fixed paraffin-embedded blocks from the prostate biopsy and/or radical prostatectomy.
• •9. Acceptable hematological, hepatic and renal functions.